La chaîne d'options affiche les données clés des options sur actions de Inovio Pharmaceuticals à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Inovio Pharmaceuticals..

Inovio Pharmaceuticals (NASDAQ:INO) Stock, Chaîne d'Options

INOVIO PHARMACEUTICALS INC

Inovio Pharmaceuticals

Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals Inc

Innodata Inc

IN OVATIONS HOLDINGS INC by In Ovations Holdings, Inc.

In Ovations Holdings Inc

TPT Strategic Inc

Predictiv AI Inc

Innovator ETFs Trust Innovator International Developed Power Buffer ETF November

InfoNow Corp

RBC Capital analyst Gregory Renza reiterates Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Sector Perform and maintains $5 price target.

News

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Sector Perform on Inovio Pharmaceuticals, Maintains $5 Price Target

Oppenheimer analyst Jay Olson maintains Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Outperform and lowers the price target from $15 to $13.

Oppenheimer Maintains Outperform on Inovio Pharmaceuticals, Lowers Price Target to $13

Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) reported quarterly losses of $(0.51) per share. This is a 61.07 percent increase over losses of $(1.31) per share from the same period last year. The company reported $65.34 thousand in sales this quarter.

Earnings

Inovio Pharmaceuticals Q1 EPS $(0.51) Up From $(1.31) YoY, Sales $65.34K Up from 0 YoY

ABOS

ABSI

ACCS

ACHV

ACXP

ADAP

ALCO

ALLO

ASNS

AUID

AVXL

BDSX

BEAT

BKTI

BWAY

BWEN

CAMT

CAPR

CINT

CLPT

CLRB

CNCK

CYBR

DARE

DLPN

DMAC

ELMD

ETON

EXEL

FENC

FLOC

FTHM

GAIN

GAUZ

GENK

GEVO

GNSS

GOCO

GRAL

GUTS

HSON

HUMA

HUYA

HYFM

HYLN

HYPR

ICMB

IMOS

INLX

IRIX

ITRM

IZEA

KOPN

KRMN

LCTX

LEGN

LOAR

LSTR

LUNR

LXRX

MASS

MBRX

MCHX

MDAI

MGNX

MPTI

NMTC

NPCE

NUTX

NUWE

NXGL

NYAX

OKLO

ONON

OPXS

PERI

PRTS

PSFE

PXLW

Earnings Scheduled For May 13, 2025

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>INO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$2.00</td>
<td>$30.8K</td>
<td align="right">332</td>
<td>4.0K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/02/25</td>
<td>$820.00</td>
<td>$35.4K</td>
<td align="right">141</td>
<td>1.1K</td>
</tr>
<tr>
<td>RARE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$45.00</td>
<td>$44.3K</td>
<td align="right">255</td>
<td>1.0K</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$182.50</td>
<td>$28.8K</td>
<td align="right">780</td>
<td>752</td>
</tr>
<tr>
<td>LNTH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$100.00</td>
<td>$81.1K</td>
<td align="right">468</td>
<td>324</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$165.00</td>
<td>$79.9K</td>
<td align="right">302</td>
<td>65</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$85.00</td>
<td>$34.1K</td>
<td align="right">236</td>
<td>59</td>
</tr>
<tr>
<td>PODD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$260.00</td>
<td>$35.7K</td>
<td align="right">5</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding INO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>), we observe a call option sweep with bearish sentiment. It expires in 204 day(s) on November 21, 2025. Parties traded 684 contract(s) at a $2.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $30.8K, with a price of $45.0 per contract. There were 332 open contracts at this strike prior to today, and today 4000 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bearish sentiment. It expires in 1 day(s) on May 2, 2025. Parties traded 43 contract(s) at a $820.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $35.4K, with a price of $836.0 per contract. There were 141 open contracts at this strike prior to today, and today 1130 contract(s) were bought and sold. 
• For RARE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), we notice a call option sweep that happens to be bullish, expiring in 106 day(s) on August 15, 2025. This event was a transfer of 80 contract(s) at a $45.00 strike. This particular call needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $44.3K, with a price of $560.0 per contract. There were 255 open contracts at this strike prior to today, and today 1028 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option sweep that happens to be bearish, expiring in 15 day(s) on May 16, 2025. This event was a transfer of 22 contract(s) at a $182.50 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.8K, with a price of $1310.0 per contract. There were 780 open contracts at this strike prior to today, and today 752 contract(s) were bought and sold. 
• For LNTH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), we notice a put option sweep that happens to be bearish, expiring in 15 day(s) on May 16, 2025. This event was a transfer of 163 contract(s) at a $100.00 strike. This particular put needed to be split into 53 different trades to become filled. The total cost received by the writing party (or parties) was $81.1K, with a price of $500.0 per contract. There were 468 open contracts at this strike prior to today, and today 324 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option trade that happens to be bearish, expiring in 624 day(s) on January 15, 2027. This event was a transfer of 65 contract(s) at a $165.00 strike. The total cost received by the writing party (or parties) was $79.9K, with a price of $1230.0 per contract. There were 302 open contracts at this strike prior to today, and today 65 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option trade that happens to be bearish, expiring in 413 day(s) on June 18, 2026. This event was a transfer of 33 contract(s) at a $85.00 strike. The total cost received by the writing party (or parties) was $34.1K, with a price of $1035.0 per contract. There were 236 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold. 
• For PODD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), we notice a put option sweep that happens to be bullish, expiring in 260 day(s) on January 16, 2026. This event was a transfer of 10 contract(s) at a $260.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $35.7K, with a price of $3570.0 per contract. There were 5 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

LNTH

PODD

RARE

8 Health Care Stocks Whale Activity In Today's Session

WIIM

ACVA

AXON

CTAS

EOSE

FRGT

FTAI

GTLS

JBLU

MNTS

PAYC

PCTY

RAIL

SATL

WLFC

Shares of industrial stocks are trading lower following greater-than-expected inflation data measured through the PCE price index for February, while personal spending missed estimates. Additionally, recent tariff announcements may be weighing on equities.

RBC Capital analyst Gregory Renza maintains Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Sector Perform and lowers the price target from $6 to $5.

RBC Capital Maintains Sector Perform on Inovio Pharmaceuticals, Lowers Price Target to $5

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Neutral and maintains $3 price target.

HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $3 Price Target

Earnings Beats

Inovio Pharmaceuticals Q4 2024 GAAP EPS $(0.65) Beats $(0.90) Estimate, Sales $117.000K Beat $30.000K Estimate

<h3>Companies Reporting Before The Bell</h3>
• Bitcoin Depot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTM#NASDAQ">BTM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $131.50 million. 
• United Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEA#NASDAQ">USEA</a>) is expected to report quarterly loss at $0.41 per share on revenue of $9.50 million. 
• Flowco Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLOC#NYSE">FLOC</a>) is estimated to report quarterly earnings at $0.35 per share on revenue of $185.00 million. 
• Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $10.68 million. 
• MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) is expected to report earnings for its fourth quarter. 
• Citi Trends (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRN#NASDAQ">CTRN</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $211.54 million. 
• McEwen Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUX#NYSE">MUX</a>) is projected to report earnings for its fourth quarter. 
• ZKH Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) is estimated to report earnings for its fourth quarter. 
• HUYA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUYA#NYSE">HUYA</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $215.25 million. 
• XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) is projected to report earnings for its fourth quarter. 
• UP Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) is expected to report earnings for its fourth quarter. 
• KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $4.01 billion. 
• Tencent Music Enter Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $1.01 billion. 
• Bakkt Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) is likely to report earnings for its fourth quarter. 
• OneConnect Financial Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OCFT#NYSE">OCFT</a>) is likely to report earnings for its fourth quarter. 
• IHS Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $413.76 million. 
• Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) is projected to report earnings for its fourth quarter. 
• Elbit Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>) is estimated to report quarterly earnings at $1.95 per share on revenue of $1.78 billion. 
• SNDL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) is expected to report earnings for its fourth quarter. 
• NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is projected to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• ZTO Express (Cayman) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>) is likely to report quarterly earnings at $0.46 per share on revenue of $1.66 billion. 
• Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) is estimated to report quarterly loss at $0.93 per share on revenue of $30 thousand. 
• Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) is projected to report earnings for its fourth quarter. 
• LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) is estimated to report earnings for its fourth quarter. 
• Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) is likely to report earnings for its fourth quarter. 
• Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) is projected to report quarterly loss at $1.19 per share on revenue of $26.90 million. 
• Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) is estimated to report quarterly loss at $0.63 per share on revenue of $23.69 million. 
• Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) is likely to report quarterly loss at $0.21 per share on revenue of $1.82 million. 
• OmniAb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) is likely to report quarterly loss at $0.10 per share on revenue of $10.13 million. 
• HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is estimated to report quarterly earnings at $0.72 per share on revenue of $305.07 million. 
• StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) is projected to report quarterly earnings at $0.35 per share on revenue of $647.56 million. 
• Waldencast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) is likely to report quarterly loss at $0.25 per share on revenue of $272.22 million. 
• Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) is likely to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATER

BEKE

BETR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

CTRN

ESLT

INKT

OABI

OCFT

ORLA

SNDL

SRFM

STNE

TIGR

TRVI

USEA

WALD

XPEV

Earnings Scheduled For March 18, 2025

Citizens Capital Markets analyst Roy Buchanan reiterates Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Market Outperform and maintains $18 price target.

Citizens Capital Markets Reiterates Market Outperform on Inovio Pharmaceuticals, Maintains $18 Price Target

<ul>
<li>Long-lasting in&nbsp;vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint</li>
<li>No anti-drug antibodies (ADA): no immune rejection of the&nbsp;DMAbs was detected across ~1,000 blood samples, unlike other gene-based antibody delivery approaches where ADA formation has been a challenge</li>
<li>Well-tolerated: most common side effects were mild, temporary injection site reactions such as pain and redness; no serious adverse events (SAEs) related to study drug</li>
<li>Effective target binding: expressed&nbsp;DMAbs successfully bound to the SARS-CoV-2 Spike protein receptor-binding domain (RBD), confirming functional activity through week 72</li>
</ul>

Reported Earlier, INOVIO Announces 72-Week Data From COVID-19 DNA Antibody Trial With No Serious Adverse Events Or Immune Reactions

Biotech

General

INOVIO Announces Phase 1/2 Trial Results Of INO-3107 For Recurrent Respiratory Papillomatosis With 81% Of Patients Requiring Fewer Surgeries; Plans BLA Submission In Mid-2025 For FDA Accelerated Approval, Aiming To Achieve First US DNA Medicine Approval

Inovio Announces That An Abstract Describing The Immunological Activity Of INO-3107 Will Be Presented As A Poster At The American Association For Cancer Research

<a href="https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004">https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004</a>
&nbsp;
A new case of Mpox has been confirmed in the UK, the UK Health Security Agency (UKHSA) has said.
The latest case of Clade Ib Mpox is the seventh confirmed case since October 2024 after a sixth patient <a href="https://www.manchestereveningnews.co.uk/news/uk-news/new-mpox-case-detected-uk-30823540">was admitted to hospital last week</a>.
<a href="https://www.gov.uk/government/news/ukhsa-detects-first-case-of-clade-ib-mpox?utm_medium=email&amp;utm_campaign=govuk-notifications-topic&amp;utm_source=d72f8bd1-0516-4336-9e7d-b4f8a791ba9a&amp;utm_content=immediately">The UKHSA says</a> the infected patient had recently travelled to Uganda and that the risk to the UK population "remains low". The UKHSA and <a href="https://www.manchestereveningnews.co.uk/all-about/nhs">NHS</a> says it will not be disclosing any further details about the infected person.
Professor Susan Hopkins, Chief Medical Adviser at UKHSA, said: "The risk to the UK population remains low. Close contacts have been identified and offered appropriate advice in order to reduce the chance of further spread."
Mpox, previously known as monkeypox, is a rare infection most commonly found in parts of central and east Africa.
There is currently community transmission of the virus in Uganda, which has so far recorded <a href="https://www.afro.who.int/countries/uganda/publication/mpox-outbreak-uganda-situation-update-22-january-2025">2,209 confirmed Mpox cases</a> and 13 deaths since July 2024.
The Clade Ib variant is a new form of the virus, the which the World Health Organisation (WHO) declared as a global health emergency in August.
WHO says common symptoms of Mpox include a skin rash or lesions which can last two to four weeks, as well as a fever, headache, muscle aches, back pain, low energy and swollen lymph nodes.
<a href="https://www.nhs.uk/conditions/mpox/">The NHS says</a> Mpox can be passed on from person to person through:
Close physical contact with Mpox blisters or scabs
Touching clothing, bedding or towels used by someone with Mpox
The coughs or sneezes of a person with Mpox when they're close to you

AEMD

APDN

CMRX

GOVX

MRNA

TNXP

VRAX

"New Case Of Mpox Detected In The UK After 'Concerning' Surge In Cases In Uganda" - Manchester Evening News

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Neutral and lowers the price target from $5 to $3.

HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $3

JMP Securities analyst Roy Buchanan reiterates Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Market Outperform and maintains $18 price target.

JMP Securities Reiterates Market Outperform on Inovio Pharmaceuticals, Maintains $18 Price Target

Shares of Inovio Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) pulled back by 5.3% to $2.16 during Wednesday's session, following a <a href="https://www.benzinga.com/news/25/01/42857690/why-inovio-pharmaceuticals-ino-stock-is-skyrocketing">strong rally</a> Tuesday.
The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses, with increased cases of influenza, COVID-19 and RSV <a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">driving interest</a> in vaccine developers.
What Else: Inovio's lead candidate, INO-4800, a DNA-based COVID-19 vaccine, remains a key focus among vaccine-makers, particularly as alternative vaccine technologies gain traction. The company is also advancing its broader pipeline, which includes vaccines for RSV, MERS and other pathogens.
While Wednesday's profit-taking reflects typical market volatility following a sharp rise, Inovio's long-term prospects remain tied to its ability to advance its portfolio and demonstrate the effectiveness of its DNA-based vaccine platform in addressing global health challenges.
Read Also: <a href="https://www.benzinga.com/25/01/42878295/quantum-stocks-tumble-why-rigetti-ionq-and-d-wave-are-falling">Quantum Stocks Tumble: Why Rigetti, IonQ and D-Wave Are Falling</a>
<h2 class="wp-block-heading">How To Buy INO Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Inovio Pharmaceuticals&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, INO has a 52-week high of $14.75 and a 52-week low of $1.74.

What's Going On With Inovio Pharmaceuticals (INO) Stock?

Inovio Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares are trading higher by 17.9% to $2.27 Tuesday afternoon amid growing concerns about <a href="https://www.cdc.gov/respiratory-viruses/data/index.html#cdc_data_surveillance_section_2-weekly-national-summary">respiratory illnesses</a>, including seasonal influenza, COVID-19 and RSV. Increased attention to vaccine and therapeutic solutions this week has increased interest in biotechnology stocks focused on infectious diseases.
The Louisiana Department of Health also <a href="https://www.ldh.la.gov/news/H5N1-death">reported</a> the first U.S. H5N1 death, a patient over 65 with underlying conditions who contracted the virus from birds, with no further cases or person-to-person spread. This may increase demand for avian flu vaccines and research.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally</a>
What Else: Inovio is known for its DNA-based vaccine technology platform. The company's lead product candidate, INO-4800, a DNA-based COVID-19 vaccine, remains a focal point of its pipeline, particularly for markets seeking alternatives to traditional mRNA vaccines.
Inovio's portfolio extends beyond COVID-19. The company is advancing research on vaccines targeting a variety of infectious diseases and cancers, with recent progress in its RSV and MERS vaccine programs. 
Additionally, its SynCon platform, which underpins its DNA medicines, enables the design and production of new vaccine candidates, potentially positioning Inovio as a player in responding to emerging global health threats.
Read Also: <a href="https://www.benzinga.com/news/25/01/42851023/why-novavax-nvax-stock-is-rising">Why Novavax Stock Is Rising</a>
<h2 class="wp-block-heading">How To Buy INO Stock</h2>
By now you're likely curious about how to participate in the market for Inovio Pharmaceuticals &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the case of Inovio Pharmaceuticals, which is trading at $2.33 as of publishing time, $100 would buy you 42.92 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.

Why Inovio Pharmaceuticals (INO) Stock Is Skyrocketing

BNTX

CVAC

NVAX

Shares of vaccine makers are trading higher after the first bird flu death was reporting in the US. Additionally, a recent CDC report noted an increase in acute respiratory illness activity.

Press Releases

INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025

INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19

INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

INOVIO to Present at Upcoming Scientific Conferences

INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

INOVIO to Present at Upcoming Scientific and Investor Conferences

INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Comments

Inovio Pharmaceuticals

Inovio Pharmaceuticals (INO) Options

Inovio Pharmaceuticals (NASDAQ:INO) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL